Nektar Therapeutics buy Global_Player
Start price
23.01.23
/
50%
€2.02
Target price
23.01.24
-
Performance (%)
-28.00%
End price
03.03.23
€1.46
Summary
This prediction ended on 03.03.23 with a price of €1.46. The prediction for Nektar Therapeutics disappointed with a performance of -28.00%. Global_Player has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | 4.329% | 4.329% | 77.755% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% |
According to Global_Player what are the pros and cons of Nektar Therapeutics for the foreseeable future?
Pros
Cons
Risky Investment
Comments by Global_Player for this prediction
In the thread Nektar Therapeutics diskutieren
Buy Nektar Therapeutics
In the thread Trading Nektar Therapeutics
Stopped prediction by Global_Player for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€1.50
11.04.24
11.04.24
-
11.04.25
11.04.25
3.27%
14.04.24
14.04.24
Risky Investment
Nektar Therapeutics
Start price
Target price
Perf. (%)
€9.30
02.02.22
02.02.22
-
02.02.23
02.02.23
-2.26%
06.02.22
06.02.22
Risky Investment